R
Roberto Nitsch
Researcher at AstraZeneca
Publications - 27
Citations - 1938
Roberto Nitsch is an academic researcher from AstraZeneca. The author has contributed to research in topics: Genome editing & CRISPR. The author has an hindex of 18, co-authored 27 publications receiving 1567 citations. Previous affiliations of Roberto Nitsch include University of Pennsylvania & Austrian Academy of Sciences.
Papers
More filters
Journal ArticleDOI
A dual role for autophagy in a murine model of lung cancer
Shuan Rao,Luigi Tortola,Thomas Perlot,Gerald Wirnsberger,Maria Novatchkova,Roberto Nitsch,Peter Sykacek,Lukas Frank,Daniel Schramek,Vukoslav Komnenovic,Verena Sigl,Karin Aumayr,Gerald Schmauss,Nicole Fellner,Stephan Handschuh,Martin Glösmann,Pawel Pasierbek,Michaela Schlederer,Guenter P. Resch,Yuting Ma,Yuting Ma,Yuting Ma,Heng Yang,Heng Yang,Heng Yang,Helmuth Popper,Lukas Kenner,Guido Kroemer,Josef M. Penninger +28 more
TL;DR: Tissue-specific inactivation of Atg5, essential for the formation of autophagosomes, markedly impairs the progression of KRas(G12D)-driven lung cancer, resulting in a significant survival advantage of tumour-bearing mice, suggesting a link between deregulated autophagy and regulatory T cell controlled anticancer immunity.
Journal ArticleDOI
The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
Magdalena Paolino,Axel Choidas,Stephanie Wallner,Blanka Pranjic,Iris Uribesalgo,Stefanie Loeser,Amanda M. Jamieson,Wallace Y. Langdon,Fumiyo Ikeda,Juan Pablo Fededa,Shane J. F. Cronin,Roberto Nitsch,Carsten Schultz-Fademrecht,Jan Eickhoff,Sascha Menninger,Anke Unger,Robert Torka,Thomas Gruber,Reinhard Hinterleitner,Gottfried Baier,Dominik Wolf,Axel Ullrich,Bert Klebl,Josef M. Penninger +23 more
TL;DR: This novel TAM/Cbl-b inhibitory pathway shows that it might be possible to develop a ‘pill’ that awakens the innate immune system to kill cancer metastases, and the anticoagulant warfarin exerts anti-metastatic activity in mice via Cbl- b/TAM receptors in NK cells.
Journal ArticleDOI
In vivo CRISPR editing with no detectable genome-wide off-target mutations
Pinar Akcakaya,Maggie L. Bobbin,Jimmy A. Guo,Jose Malagon-Lopez,Kendell Clement,Sara P. Garcia,Mick D. Fellows,Michelle J. Porritt,Mike Firth,Alba Carreras,Alba Carreras,Tania Baccega,Frank Seeliger,Mikael Bjursell,Shengdar Q. Tsai,Nhu T. Nguyen,Roberto Nitsch,Lorenz M. Mayr,Lorenz M. Mayr,Luca Pinello,Mohammad Bohlooly-Y,Martin J. Aryee,Marcello Maresca,J. Keith Joung +23 more
TL;DR: VIVO provides a general strategy for defining and quantifying the off-target effects of gene-editing nucleases in whole organisms, thereby providing a blueprint to foster the development of therapeutic strategies that use in vivo gene editing.
Journal ArticleDOI
The Paired Domain-containing Factor Pax8 and the Homeodomain-containing Factor TTF-1 Directly Interact and Synergistically Activate Transcription
TL;DR: A functional cooperation and a physical interaction between transcription factors of the homeodomain-containing and of the paired domain-containing gene families in the regulation of tissue-specific gene expression is demonstrated.
Journal ArticleDOI
CRISPR-UMI: single-cell lineage tracing of pooled CRISPR–Cas9 screens
Georg Michlits,Maria Hubmann,Szu-Hsien Wu,Gintautas Vainorius,Budusan Elena,Sergei Zhuk,Thomas R Burkard,Thomas R Burkard,Maria Novatchkova,Maria Novatchkova,Martin Aichinger,Yiqing Lu,Yiqing Lu,John S. Reece-Hoyes,Roberto Nitsch,Daniel Schramek,Daniel Schramek,Dominic Hoepfner,Ulrich Elling +18 more
TL;DR: CRISPR-UMI boosts the predictive power, sensitivity, and information content of pooled CRISPR screens by accounting for underlying cellular and editing-outcome heterogeneity and detection of outlier clones.